Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Evodia radix, derived from the root of *Evodia rutaecarpa*, is a traditional Chinese medicinal substance being investigated by the Fifth Medical Center of PLA General Hospital for the treatment of chronic non-atrophic gastritis. The pharmacological activity is primarily attributed to quinolone alkaloids such as evodiamine and rutaecarpine. These compounds exhibit potent anti-inflammatory effects by inhibiting the NF-κB signaling pathway and reducing the production of pro-inflammatory cytokines like TNF-α and IL-6. Additionally, evodiamine acts as a transient receptor potential vanilloid 1 (TRPV1) agonist, which may play a role in modulating gastric mucosal blood flow and pain perception. In the context of chronic gastritis, Evodia radix is studied for its ability to protect the gastric mucosa, inhibit *Helicobacter pylori* growth, and alleviate symptoms associated with gastric inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on evodia radix.